Schering-Plough subsidiary and company sign agreement

Schering-Plough’s subsidiary V Organon has said it has signed an agreement with Huya Bioscience.

The partnership will see Huya identifying and presenting to Schering-Plough on an exclusive basis proprietary lead.

Schering-Plough will also gain access to Huya’s bioscience network, comprising of universities, government research institutions and bioparks.

Mirielle Gingras, president and chief executive officer of Huya, said: “Our agreement with Schering-Plough demonstrates both the effectiveness of our network ? and our ability to leverage that network to benefit major development partners.”

She added the company was “delighted” to be forging the new alliance and looked forward to a “fruitful collaboration”.

Huya currently has two drugs undergoing preclinical development, HBI-3000 and HBI-8000.

The products are for cardiac fibrillation and oncology respectively.

Earlier this week, Schering-Plough announced it had received marketing approval for its Pegintron and Rebetol combination therapy.

Based on the results of a clinical trial, it is the first and only Pegintron in combination with Rebetol therapy to be approved, the company said.

The drug is for use in previously untreated patients three years of age and older, who have chronic hepatitis C.

Speaking at the time, Robert Spiegel, chief medical officer of Schering-Plough Research Institute, said the approval means physicians now have access to the “current standard of care”.